MLTX - MoonLake Immunotherapies

-

$undefined

N/A

(N/A)

MoonLake Immunotherapies NasdaqCM:MLTX MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Location: Dorfstrasse 29, Zug, 6300, Switzerland | Website: https://www.moonlaketx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.073B

Cash

480.1M

Avg Qtr Burn

-34.94M

Short % of Float

21.37%

Insider Ownership

15.34%

Institutional Own.

96.89%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Sonelokimab Details
Hidradenitis suppurativa

Phase 3

Data readout

Sonelokimab Details
Psoriatic arthritis

Phase 3

Data readout

Sonelokimab Details
Hidradenitis suppurativa

Phase 3

Data readout

Sonelokimab Details
Axial spondyloarthritis

Phase 2

Data readout

Sonelokimab Details
Palmoplantar pustulosis

Phase 2

Data readout

Sonelokimab Details
Psoriatic arthritis and Axial spondyloarthritis

Phase 2

Initiation